Skip to main content
Signal8
Launch Terminal

BeOne Medicines Ltd. (ONC)

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BeOne Medicines AG logo

BeOne Medicines AG

NASDAQ:ONCHealthcare
-0.33%$370.33
AH$370.33+0.00%vs close
Mkt Cap$41.89B
Float60.73M
O/S113.12M
Vol
$ Vol
RVOL
Inst Own22.5%
SI3.0%
Earnings
Dilution
BeOne Medicines AG logoNASDAQ:ONC$370.33-0.33%
Upcoming Catalysts
Phase Distribution
193 lead-sponsored trials·58 active·103 completed
Phase 185
Phase 1/222
Phase 245
Phase 2/31
Phase 336
Phase 41
Not applicable3
(92 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Active, not recruiting

    A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

    Zanubrutinib

    Waldenström's Macroglobulinemia

    Enrollment
    16
    Start
    Oct 2025
    Primary Completion
    Oct 2028est.
    Completion
    Oct 2028est.
    NCT07169331
  • Phase 3
    Completed

    A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

    BGB-3111, Ibrutinib

    Waldenström's Macroglobulinemia

    Enrollment
    201
    Start
    Jan 2017
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT03053440
  • Phase 3
    Active, not recruiting

    A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

    Zanubrutinib, Bendamustine

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

    Enrollment
    590
    Start
    Oct 2017
    Primary Completion
    May 2021
    Completion
    Oct 2027est.
    NCT03336333
  • Phase 3
    Completed

    Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

    Tislelizumab, Docetaxel

    Non-small Cell Lung Cancer

    Enrollment
    805
    Start
    Nov 2017
    Primary Completion
    Jul 2021
    Completion
    Jan 2024
    NCT03358875
  • Phase 3
    Completed

    A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

    Tislelizumab, Sorafenib

    Hepatocellular Carcinoma (HCC)

    Enrollment
    684
    Start
    Dec 2017
    Primary Completion
    Jul 2022
    Completion
    Dec 2023
    NCT03412773
  • Phase 3
    Completed

    A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

    Tislelizumab, Paclitaxel

    Esophageal Squamous Cell Carcinoma (ESCC)

    Enrollment
    512
    Start
    Jan 2018
    Primary Completion
    Dec 2020
    Completion
    Dec 2022
    NCT03430843
  • Phase 3
    Active, not recruiting

    Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

    Pamiparib capsule, Placebo capsule

    Ovarian Cancer

    Enrollment
    224
    Start
    May 2018
    Primary Completion
    Dec 2025
    Completion
    Jan 2027est.
    NCT03519230
  • Phase 3
    Completed

    A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

    Tislelizumab, Paclitaxel

    Non-Small Cell Lung Cancer

    Enrollment
    360
    Start
    Jul 2018
    Primary Completion
    Sep 2020
    Completion
    Apr 2023
    NCT03594747
  • Phase 3
    Completed

    A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

    Tislelizumab, Cisplatin

    Non-Small Cell Lung Cancer

    Enrollment
    334
    Start
    Jul 2018
    Primary Completion
    Jan 2020
    Completion
    Apr 2023
    NCT03663205
  • Phase 3
    Completed

    A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Zanubrutinib, Ibrutinib

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

    Enrollment
    652
    Start
    Nov 2018
    Primary Completion
    Aug 2022
    Completion
    Feb 2024
    NCT03734016
  • Phase 3
    Completed

    Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

    Tislelizumab, Placebo

    Gastric, or Gastroesophageal Junction Adenocarcinoma

    Enrollment
    997
    Start
    Dec 2018
    Primary Completion
    Feb 2023
    Completion
    Aug 2024
    NCT03777657
  • Phase 3
    Completed

    A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

    Cisplatin, Oxaliplatin

    Esophageal Squamous Cell Carcinoma (ESCC)

    Enrollment
    649
    Start
    Dec 2018
    Primary Completion
    Feb 2022
    Completion
    Aug 2024
    NCT03783442
  • Phase 3
    Completed

    Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

    Tislelizumab, Placebo

    Recurrent or Metastatic Nasopharyngeal Cancer

    Enrollment
    263
    Start
    Mar 2019
    Primary Completion
    Mar 2021
    Completion
    Dec 2023
    NCT03924986
  • Phase 3
    Completed

    A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

    Tislelizumab, Placebo

    Esophageal Squamous Cell Carcinoma (ESCC)

    Enrollment
    370
    Start
    Jun 2019
    Primary Completion
    Jan 2025
    Completion
    Mar 2025
    NCT03957590
  • Phase 3
    Active, not recruiting

    Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

    Tislelizumab, Placebo

    Urothelial Carcinoma

    Enrollment
    420
    Start
    May 2019
    Primary Completion
    Jun 2027est.
    Completion
    Oct 2027est.
    NCT03967977
  • Phase 3
    Active, not recruiting

    A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

    zanubrutinib, bendamustine

    Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

    Enrollment
    510
    Start
    Aug 2019
    Primary Completion
    Apr 2026
    Completion
    Sep 2031est.
    NCT04002297
  • Phase 3
    Completed

    Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

    Tislelizumab, Cisplatin

    Small Cell Lung Cancer

    Enrollment
    457
    Start
    Jul 2019
    Primary Completion
    Apr 2023
    Completion
    Dec 2023
    NCT04005716
  • Phase 3
    Completed

    Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

    Tislelizumab, Pamiparib

    Advanced Malignancies

    Enrollment
    404
    Start
    Dec 2019
    Primary Completion
    May 2026
    Completion
    May 2026
    NCT04164199
  • Phase 3
    Active, not recruiting

    A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

    Zanubrutinib, Tislelizumab

    B-cell Malignancies

    Enrollment
    955
    Start
    Jan 2020
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT04170283
  • Phase 3
    Active, not recruiting

    Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

    Tislelizumab, Cisplatin injection

    Non Small Cell Lung Cancer

    Enrollment
    453
    Start
    May 2020
    Primary Completion
    Aug 2023
    Completion
    Mar 2027est.
    NCT04379635
  • Phase 3
    Terminated

    Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

    Tislelizumab, Salvage Chemotherapy

    Classical Hodgkin Lymphoma

    Enrollment
    3
    Start
    Dec 2020
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT04486391
  • Phase 3
    Terminated

    A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

    Tislelizumab, Ociperlimab

    Non-small Cell Lung Cancer, NSCLC

    Enrollment
    669
    Start
    May 2021
    Primary Completion
    May 2025
    Completion
    Mar 2026
    NCT04746924
  • Phase 3
    Terminated

    A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

    Tislelizumab, Durvalumab

    Non Small Cell Lung Cancer

    Enrollment
    63
    Start
    Jun 2021
    Primary Completion
    Oct 2023
    Completion
    Oct 2023
    NCT04866017
  • Phase 3
    Terminated

    Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Tislelizumab, Docetaxel

    Non-Small Cell Lung Cancer (NSCLC)

    Enrollment
    377
    Start
    Jul 2021
    Primary Completion
    Dec 2023
    Completion
    Dec 2023
    NCT04921358
  • Phase 3
    Active, not recruiting

    A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

    Zanubrutinib, Rituximab

    Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

    Enrollment
    799
    Start
    Mar 2022
    Primary Completion
    Jul 2028est.
    Completion
    Jun 2030est.
    NCT05100862

1-25 of 193

…
Search ClinicalTrials.gov for “BeOne Medicines”